Abstract
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Ursula Mason, Jose Aldrich, Ferdinand Breedveld, Charles B Davis, Michael Elliott, Mildred Jackson, Christian Jorgensen, Edward Keystone, Robert Levy, John Tesser, Mark Totoritis, Alemseged Truneh, Michael Weisman, Craig Wiesenhutter, David Yocum and Jin Zhu
The Journal of Rheumatology February 2002, 29 (2) 220-229;
Ursula Mason
Jose Aldrich
Ferdinand Breedveld
Charles B Davis
Michael Elliott
Mildred Jackson
Christian Jorgensen
Edward Keystone
Robert Levy
John Tesser
Mark Totoritis
Alemseged Truneh
Michael Weisman
Craig Wiesenhutter
David Yocum
In this issue
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Ursula Mason, Jose Aldrich, Ferdinand Breedveld, Charles B Davis, Michael Elliott, Mildred Jackson, Christian Jorgensen, Edward Keystone, Robert Levy, John Tesser, Mark Totoritis, Alemseged Truneh, Michael Weisman, Craig Wiesenhutter, David Yocum, Jin Zhu
The Journal of Rheumatology Feb 2002, 29 (2) 220-229;
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Ursula Mason, Jose Aldrich, Ferdinand Breedveld, Charles B Davis, Michael Elliott, Mildred Jackson, Christian Jorgensen, Edward Keystone, Robert Levy, John Tesser, Mark Totoritis, Alemseged Truneh, Michael Weisman, Craig Wiesenhutter, David Yocum, Jin Zhu
The Journal of Rheumatology Feb 2002, 29 (2) 220-229;